DOCSLIB.ORG

Caremark Confidential and Proprietary Information. Not for Distribution

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Caremark Confidential and Proprietary Information. Not for distribution © 2017 Caremark. All rights reserved. This document contains confidential and proprietary information of Caremark and cannot be reproduced, distributed or printed without the prior written consent of Caremark. MAC drugs and prices are subject to change. Accordingly, the drugs and prices on this MAC list are applicable only as to the date of this list. Indicated MAC prices are the lowest MAC unit price applicable across all pharmacies for the Highmark Health Options pharmacy network. Highmark Health Options MAC List July 1, 2021 Drug Name Dosage Form Strength Pkg Size MAC/unit Penicillin V Potassium TAB 250mg 999 0.1092 Penicillin V Potassium TAB 500mg 999 0.0870 Amoxicillin CAP 250mg 999 0.0792 Amoxicillin CAP 500mg 999 0.0724 Amoxicillin TAB 500mg 999 0.1481 Amoxicillin TAB 875mg 999 0.0752 Amoxicillin PDR 125mg / 5ml, 80ml 80 0.0350 Amoxicillin PDR 125mg / 5ml, 100ml 100 0.0274 Amoxicillin PDR 125mg / 5ml, 150ml 150 0.0239 Amoxicillin SUS 200/5ml, 50ml 50 0.0711 Amoxicillin SUS 200/5ml, 75ml 75 0.0506 Amoxicillin SUS 200/5ml, 100ml 100 0.0380 Amoxicillin PDR 250mg / 5ml, 80ml 80 0.0211 Amoxicillin PDR 250mg / 5ml, 100ml 100 0.0211 Amoxicillin PDR 250mg / 5ml, 150ml 150 0.0177 Amoxicillin SUS 400/5ml, 50ml 50 0.0501 Amoxicillin SUS 400/5ml, 75ml 75 0.0488 Amoxicillin SUS 400/5ml, 100ml 100 0.0399 Dicloxacillin Sodium CAP 250mg 999 0.2434 Dicloxacillin Sodium CAP 500mg 999 0.4610 Amoxicillin/Clavulanic Acid TAB 250mg 999 2.7350 Amoxicillin/Clavulanic Acid TAB 500mg 999 0.1896 Amoxicillin/Clavulanic Acid TAB 875mg 999 0.1824 Amoxicillin/Clavulanic Acid SUS 200mg, 50ml 50 0.2665 Amoxicillin/Clavulanic Acid SUS 200mg, 75ml 75 0.2372 Amoxicillin/Clavulanic Acid SUS 200mg, 100ml 100 0.2612 Amoxicillin/Clavulanic Acid SUS 250mg/5ml 75 0.7844 Amoxicillin/Clavulanic Acid SUS 250mg/5ml 100 0.7855 Amoxicillin/Clavulanic Acid SUS 250mg/5ml 150 0.7695 Amoxicillin/Clavulanic Acid SUS 400mg, 50mg 50 0.0765 Amoxicillin/Clavulanic Acid SUS 400mg, 75mg 75 0.0765 Amoxicillin/Clavulanic Acid SUS 400mg, 100mg 100 0.0765 Amoxicillin/Clavulanic Acid SUS 600-42.9mg/5ml 75 0.0351 Amoxicillin/Clavulanic Acid SUS 600-42.9mg/5ml 125 0.0351 Amoxicillin/Clavulanic Acid SUS 600-42.9mg/5ml 200 0.0351 Cefadroxil CAP 500mg 999 0.2445 Cefadroxil SUS 250mg/5ml 50 0.2918 Cefadroxil SUS 250mg/5ml 100 0.2918 Cefadroxil SUS 500mg/5ml 75 0.3706 Cefadroxil SUS 500mg/5ml 100 0.3706 Cephalexin CAP 250mg 999 0.1011 Cephalexin CAP 500mg 999 0.0744 Cephalexin PDR 125mg/5ml, 100ml 100 0.0616 Cephalexin PDR 125mg/5ml, 200ml 200 0.0616 Cephalexin PDR 250mg/5ml, 100ml 100 0.1018 Cephalexin PDR 250mg/5ml, 200ml 200 0.0752 Cefprozil TAB 250mg 999 1.1038 Cefprozil TAB 500mg 999 0.6838 Cefprozil SUS 125mg/5ml 50 0.2565 Cefprozil SUS 125mg/5ml 75 0.2565 Cefprozil SUS 125mg/5ml 100 0.2565 Cefprozil SUS 250mg/5ml 50 0.1032 Cefprozil SUS 250mg/5ml 75 0.1032 Cefprozil SUS 250mg/5ml 100 0.1032 Cefuroxime TAB 250mg 999 0.1968 Cefuroxime TAB 500mg 999 0.3591 Cefdinir CAP 300mg 999 0.3828 Cefdinir SUS 125mg/5ml 60 0.1641 Cefdinir SUS 125mg/5ml 100 0.1562 Caremark Confidential and Proprietary Information. Not for distribution © 2017 Caremark. All rights reserved. This document contains confidential and proprietary information of Caremark and cannot be reproduced, distributed or printed without the prior written consent of Caremark. MAC drugs and prices are subject to change. Accordingly, the drugs and prices on this MAC list are applicable only as to the date of this list. Indicated MAC prices are the lowest MAC unit price applicable across all pharmacies for the Highmark Health Options pharmacy network. Highmark Health Options MAC List July 1, 2021 Drug Name Dosage Form Strength Pkg Size MAC/unit Cefdinir SUS 250mg/5ml 60 0.3094 Cefdinir SUS 250mg/5ml 100 0.2914 Cefixime SUS 100mg/5ml 999 3.3003 Cefixime SUS 200mg/5ml 50 6.6338 Cefixime SUS 200mg/5ml 75 6.6338 Cefpodoxime Proxetil TAB 100mg 999 2.8541 Cefpodoxime Proxetil TAB 200mg 999 3.2948 Ceftriaxone Sodium INJ 1gm 999 2.3721 Erythromycin TAB 250mg 999 9.7854 Erythromycin TAB 500mg 999 14.7511 Erythromycin Ethylsuccinate SUS 200mg/5ml 100 2.9821 Erythromycin Ethylsuccinate SUS 200mg/5ml 200 2.6995 Erythromycin Ethylsuccinate SUS 400mg/5ml 100 5.2889 Azithromycin TAB 250 mg 999 0.4444 Azithromycin TAB 500 mg 999 0.8341 Azithromycin TAB 600 mg 999 2.0004 Azithromycin SUS, PDR 100mg / 5 ml 15 1.1088 Azithromycin SUS, PDR 200mg / 5 ml 15 0.3340 Azithromycin SUS, PDR 200mg / 5 ml 22.5 0.2228 Azithromycin SUS, PDR 200mg / 5 ml 30 0.1990 Clarithromycin TAB 250mg 999 1.0901 Clarithromycin TAB 500mg 999 0.6273 Clarithromycin XL TAB, ER 500mg 999 2.3942 Demeclocycline TAB 150mg 999 4.9063 Demeclocycline TAB 300mg 999 3.8884 Doxycycline Monohydrate CAP 50mg 999 0.2885 Doxycycline Monohydrate CAP 75mg 999 13.3106 Doxycycline Monohydrate CAP 100mg 999 0.2394 Doxycycline Monohydrate CAP 150mg 999 16.3295 Doxycycline Monohydrate TAB 50mg 999 0.5299 Doxycycline Monohydrate TAB 75mg 999 0.5831 Doxycycline Monohydrate TAB 100mg 999 0.2782 Doxycycline Monohydrate TAB 150mg 999 2.9874 Doxycycline Monohydrate SUSP 25mg/5ml 999 0.3292 Doxycycline Hyclate CAP 50mg 999 0.3653 Doxycycline Hyclate CAP 100mg 999 0.9821 Doxycycline TAB 20mg 999 0.4400 Doxycycline Hyclate TAB 75mg 999 23.1067 Doxycycline Hyclate TAB 100mg 999 0.5400 Doxycycline Hyclate TAB 150mg 999 23.1067 Doxycycline Hyclate TAB, DR 50mg 999 9.0192 Doxycycline Hyclate TAB, DR 75mg 999 8.4757 Doxycycline Hyclate TAB, DR 100mg 999 2.0358 Doxycycline Hyclate TAB, DR 150mg 999 4.1656 Doxycycline Hyclate TAB, DR 200mg 999 9.5994 Minocycline Hydrochloride CAP 50mg 999 0.1520 Minocycline Hydrochloride CAP 75mg 999 0.2753 Minocycline Hydrochloride CAP 100mg 999 0.2263 Minocycline Hydrochloride TAB 50 mg 999 1.7163 Minocycline Hydrochloride TAB 75 mg 999 2.4676 Minocycline Hydrochloride TAB 100 mg 999 0.3406 Minocycline Hydrochloride TAB, ER 45mg 999 15.6356 Minocycline HCl TAB, ER 55mg 999 30.4193 Minocycline Hydrochloride TAB, ER 65mg 999 33.0219 Minocycline HCl TAB, ER 80mg 999 9.8618 Minocycline Hydrochloride TAB, ER 90mg 999 2.7777 Minocycline HCl TAB, ER 105mg 999 9.8618 Minocycline Hydrochloride TAB, ER 115mg 999 33.0219 Minocycline Hydrochloride TAB, ER 135mg 999 2.7777 Tetracycline Hydrochloride CAP 250mg 999 1.8673 Caremark Confidential and Proprietary Information. Not for distribution © 2017 Caremark. All rights reserved. This document contains confidential and proprietary information of Caremark and cannot be reproduced, distributed or printed without the prior written consent of Caremark. MAC drugs and prices are subject to change. Accordingly, the drugs and prices on this MAC list are applicable only as to the date of this list. Indicated MAC prices are the lowest MAC unit price applicable across all pharmacies for the Highmark Health Options pharmacy network. Highmark Health Options MAC List July 1, 2021 Drug Name Dosage Form Strength Pkg Size MAC/unit Tetracycline Hydrochloride CAP 500mg 999 3.9214 Ciprofloxacin TAB 250mg 999 0.0634 Ciprofloxacin TAB 500mg 999 0.0732 Ciprofloxacin TAB 750mg 999 0.3104 Levofloxacin TAB 250mg 999 0.1977 Levofloxacin TAB 500MG 999 0.2344 Levofloxacin TAB 750MG 999 0.1450 Moxifloxacin TAB 400mg 999 7.1429 Neomycin Sulfate TAB 500mg 999 0.7083 Tobramycin NEB 300mg/5ml 999 12.0325 Ethambutol TAB 100mg 999 0.1903 Ethambutol TAB 400mg 999 1.0315 Isoniazid TAB 300mg 999 0.0687 Rifampin CAP 150mg 999 0.9245 Rifampin CAP 300mg 999 0.3950 Flucytosine CAP 250mg 999 56.1352 Flucytosine CAP 500mg 999 108.6226 Griseofulvin Microsize TAB 500mg 999 7.2928 Griseofulvin, microsize SUS 125 mg/5 ml 999 0.0854 Griseofulvin Ultramicrosize TAB 125mg 999 3.5821 Griseofulvin Ultramicrosize TAB 250mg 999 4.5705 Nystatin TAB 500,000 units 999 0.2256 Terbinafine TAB 250mg 999 0.1116 Ketoconazole TAB 200mg 999 0.2016 Fluconazole TAB 50mg 999 0.4304 Fluconazole TAB 100mg 999 0.1026 Fluconazole TAB 150mg 999 0.2442 Fluconazole TAB 200mg 999 1.2225 Fluconazole SUS 10mg/ml 999 0.2036 Fluconazole SUS 40mg/ml 999 0.5701 Itraconazole CAP 100 mg 999 1.2090 Itraconazole SOL 10mg/ml 999 1.5110 Posaconazole TAB, DR 100mg 999 26.5421 Voriconazole TAB 50mg 999 1.8240 Voriconazole TAB 200mg 999 2.5935 Voriconazole SUS 40mg/ml 999 11.0101 Atazanavir Sulfate CAP 150mg 999 4.2891 Atazanavir Sulfate CAP 200mg 999 4.2891 Atazanavir Sulfate CAP 300mg 999 8.4971 Ritonavir TAB 100mg 999 1.3776 Abacavir Sulfate TAB 300mg 999 4.2052 Lamivudine TAB 150mg 999 3.4347 Lamivudine TAB 300mg 999 6.8701 Lamivudine SOL 10mg/ml 999 0.2367 Zidovudine CAP 100mg 999 0.6716 Zidovudine TAB 300mg 999 0.2902 Zidovudine SYP 50mg/5ml 999 0.0917 Tenofovir disoproxil fumarate TAB 300mg 999 6.3112 Efavirenz TAB 600mg 999 13.1167 Nevirapine TAB 200mg 999 0.1497 Nevirapine TAB,ER 400mg 999 11.3027 Abacavir / Lamivudine TAB 600-300mg 999 7.4386 Emtricitabine / Tenofovir TAB 200mg-300mg 999 29.7529 Lamivudine / Zidovudine TAB 150mg - 300mg 999 2.4546 Efavirenz / Emtricitabine / Tenofovir TAB 600mg - 200mg - 300mg 999 48.3646 Valganciclovir TAB 450mg 999 2.9330 Entecavir TAB 0.5mg 999 19.9063 Entecavir TAB 1mg 999 19.9063 Lamivudine TAB 100mg 999 7.5270 Ribavirin CAP 200mg 999 0.7493 Caremark Confidential and Proprietary Information. Not for distribution © 2017 Caremark.
Recommended publications
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application

    Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application

    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
  • Adverse Drug Reactions Sample Chapter

    Adverse Drug Reactions Sample Chapter

    Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media.
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
  • Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F

    Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F

    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Scholarly Papers 2014 Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F. DeBellis Kimberly L. Barefield Philadelphia College of Osteopathic Medicine, [email protected] Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers Part of the Medicine and Health Sciences Commons Recommended Citation DeBellis, Heather F. and Barefield, Kimberly L., "Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia" (2014). PCOM Scholarly Papers. 1913. https://digitalcommons.pcom.edu/scholarly_papers/1913 This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Open Access: Full open access to Clinical Medicine Reviews this and thousands of other papers at http://www.la-press.com. in Therapeutics Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia Heather F. DeBellis and Kimberly L. Tackett South University School of Pharmacy, Savannah, GA, USA. ABSTR ACT: Ceftaroline fosamil is a new fifth-generation cephalosporin indicated for the treatment of community-acquired bacterial pneumonia (CABP). It possesses antimicrobial effects against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), but not against anaerobes. Organisms covered by this novel agent that are commonly associated with CABP are Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae; however, ceftaroline fosamil lacks antimicrobial activity against Pseudomonas and Acinetobacter species.
  • Methadone and Buprenorphine: Clinical Impact of Drug Interactions

    Methadone and Buprenorphine: Clinical Impact of Drug Interactions

    11/03/2014 Methadone and Buprenorphine: Clinical Impact of Drug Interactions Elinore F. McCance-Katz, MD, PhD Disclosures None Adverse Drug Interactions • Accidents: leading cause of death in the USA in those aged 1–44 with highest rates in 25–44 y.o. • Poisoning: a leading cause of accidental deaths in the US – 145% increase in 1999–2007 – Opioids most frequently named drugs in poisonings • DDIs: a leading cause of accidental poisoning deaths in the USA (CDC, 2011) – Those exposed to DDIs between CYP450-metabolized opioids and other medications have higher medical costs (Summers et al, 2011) 1 11/03/2014 Underlying Reasons for DDIs • Many with opioid dependence have co-occurring medical and / or mental disorders • Patients believe prescribed drugs are ‘safe’ • Lack of patient education about adverse events that can occur • May not understand need to take as prescribed • Sharing / selling Pathophysiology of DDIs • Pharmacokinetic (PK) – What you do to the drug (or not) – With PK interactions, one drug causes an alteration in the concentration of another drug increasing risks of side effects or reduced effectiveness of the drug • Pharmacodynamic (PD) – What the drug or drugs do to you – With PD interactions, two drugs have additive effects or antagonistic effects Pharmacodynamic Interactions • PK interactions may have associated PD consequences • PD interactions can occur in the absence of a PK interaction • Two drugs with similar pharmacological characteristics interact synergistically – Increases potential toxicity of drug – Opioids
  • Ceftaroline in Complicated Skin and Skin-Structure Infections

    Ceftaroline in Complicated Skin and Skin-Structure Infections

    Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Ceftaroline in complicated skin and skin-structure infections Paul O Hernandez1 Abstract: Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by Sergio Lema2 the US Food and Drug Administration for the treatment of complicated skin and skin-structure Stephen K Tyring3 infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity Natalia Mendoza2,4 by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially 1University of Texas School of Medicine at San Antonio, beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted San Antonio, TX, 2Woodhull clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recom- Medical and Mental Health Center, mended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness Brooklyn, NY, 3Department of Dermatology, University of Texas and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA Health Science Center at Houston, and other multidrug-resistant strains, warrants its consideration as a first-line treatment option 4 Houston, TX, USA; Department of for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to Dermatology, El
  • Amoxicillin and Clavulanic Acid)

    Amoxicillin and Clavulanic Acid)

    European Medicines Agency London, 19 October 2009 Doc. Ref. EMEA/CHMP/97898/2009 rev 1 EMEA/H/A-30/979 Questions and answers on the referral for Augmentin (amoxicillin and clavulanic acid) The European Medicines Agency has completed a review of Augmentin. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Augmentin in the European Union (EU). The review was carried out under an ‘Article 30’ referral1. What is Augmentin? Augmentin is an antibiotic. It is used for the short-term treatment of a number of common infections: • infections of the respiratory tract (airways and lungs) such as tonsillitis, sinusitis, otitis media (infection of the middle ear), exacerbation (flare up) of bronchitis and pneumonia; • infections of the urinary tract (the structures that carry urine in the body); • infections of the skin and soft tissues (the structures just below the skin); It can also be used for more serious infections, such as bone or intra-abdominal infections. It can be used in the prevention of some infections. Augmentin, also known as ‘coamoxiclav’, contains two active substances: amoxicillin, which is an antibiotic belonging to the beta-lactam family (the same family as penicillins), and clavulanic acid, which is a ‘beta-lactamase inhibitor’. When Augmentin is absorbed in the body, the amoxicillin component kills the bacteria that are causing the infection, while the clavulanic acid component blocks an enzyme, betalactamase that enable the bacteria to destroy amoxicillin. As a result, the antibiotic can work for longer, and is more effective in killing bacteria.
  • Amoxicillin-Clavulanic Acid

    Amoxicillin-Clavulanic Acid

    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ CONTRAINDICATIONS ----------------------­ These highlights do not include all the information needed to use • History of a serious hypersensitivity reaction (e.g., anaphylaxis or AUGMENTIN safely and effectively. See full prescribing Stevens-Johnson syndrome) to AUGMENTIN or to other information for AUGMENTIN. beta-lactams (e.g., penicillins or cephalosporins) (4) • History of cholestatic jaundice/hepatic dysfunction associated with AUGMENTIN (amoxicillin/clavulanate potassium) Tablets, AUGMENTIN. (4) Powder for Oral Suspension, and Chewable Tablets ----------------------- WARNINGS AND PRECAUTIONS ---------------­ Initial U.S. Approval: 1984 • Serious (including fatal) hypersensitivity reactions: Discontinue To reduce the development of drug-resistant bacteria and maintain the AUGMENTIN if a reaction occurs. (5.1) effectiveness of AUGMENTIN and other antibacterial drugs, • Hepatic dysfunction and cholestatic jaundice: Discontinue if AUGMENTIN should be used only to treat infections that are proven signs/symptoms of hepatitis occur. Monitor liver function tests in or strongly suspected to be caused by bacteria. patients with hepatic impairment. (5.2) ---------------------------- INDICATIONS AND USAGE -------------------­ • Clostridium difficile-associated diarrhea (CDAD): Evaluate AUGMENTIN is a combination penicillin-class antibacterial and patients if diarrhea occurs. (5.3) beta-lactamase inhibitor indicated for treatment of the following: • Patients with mononucleosis
  • Therapeutic Drug Class

    Therapeutic Drug Class

    MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 07/01/2017 UNIVERSAL PREFERRED DRUG LIST Version 2017.4 (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 06-21-2017 ‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ACNE AGENTS ANTI-INFECTIVE clindamycin (gel, lotion, solution) ACZONE (dapsone) Maximum Age Limit erythromycin AKNE-MYCIN (erythromycin) 21 years – all agents AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDAGEL (clindamycin) clindamycin foam ERY (erythromycin) ERYGEL (erythromycin) EVOCLIN (clindamycin) FINACEA (azelaic acid) KLARON (sulfacetamide) sulfacetamide RETINOIDS RETIN-A (tretinoin) adapalene tretinoin cream AVITA (tretinoin) ATRALIN (tretinoin) DIFFERIN (adapalene) FABIOR (tazarotene) RETIN-A MICRO (tretinoin) tazarotene TAZORAC (tazarotene) tretinoin gel tretinoin micro COMBINATION DRUGS/OTHERS EPIDUO (adapalene/benzoyl peroxide) ACANYA (benzoyl peroxide/clindamycin) erythromycin/benzoyl peroxide BENZACLIN GEL (benzoyl peroxide/clindamycin) sodium sulfacetamide/sulfur cream/foam/gel BENZACLIN KIT (benzoyl peroxide/ clindamycin) BENZAMYCIN PAK (benzoyl peroxide/ erythromycin) 1 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage
  • Two-Tier Generic Drugs

    Two-Tier Generic Drugs

    TWO-TIER Generic Medications Benefit Design What is a two-tiered generic medications benefit design? A two-tiered generic medication benefit design features a list of generic drugs with two levels of member cost-share amounts for generic prescription medications. This gives an incentive to request lower-cost generic medications whenever possible. Your cost share amount depends on which tier of the generic drug list your medication is In. Tier I: Lower-cost generic drugs. Tier II: Higher-cost generic drugs Generic drugs deliver a better value than brand-name drugs. They work the same way as brand-name drugs, but can cost between 30 and 80 percent less. 1 The medications in the list below are the lower-cost generic medications that are in Tier I of your prescription drug plan. You may use the higher-cost generic medications in Tier II, but those medications will cost you more than Tier I generics. Generic medications not listed below would follow your benefit plan out-of-pocket for Tier II. NOTE: This is a list of two-tiered generic medications. Drugs may appear on the list that may or may not be covered under your plan. This list is subject to change. If you have questions, please contact Blue Cross and Blue Shield of Nebraska’s Member Services department at the number on the back of your member ID card. 1http://www.healthsmart.com/SmarterHealth/GenericVsBrandDrugs. aspx, accessed 12 March 2013. 2021 Drug Name Drug Name ANTI-INFECTIVE AGENTS levofloxacin tab 250 mg (Levaquin) PENICILLINS levofloxacin tab 500 mg (Levaquin) amoxicillin (trihydrate)
  • Alphabetical Listing of ATC Drugs & Codes

    Alphabetical Listing of ATC Drugs & Codes

    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0